This activity is provided by Forefront Collaborative.
This online activity is supported by an educational grant from Pfizer Inc.
This certified activity will include an overview of the combined intervention plus postintervention outcomes from the Women’s Health Initiative (WHI), including stratified analyses by age and time since menopause. The expert faculty will present complicated cases of women who present with the symptoms of menopause and will provide instruction on evidence-based care based on these data and clinical practice guidelines. The faculty will highlight key clinical concerns such as genitourinary symptoms in a young, healthy woman; vasomotor symptoms despite nonhormonal therapies in a woman with a history of cardiovascular disease; and the decision-making process for extended hormone therapy vs tapering in a postmenopausal woman.
If you are looking for additional WHI resources, please visit the "How, When, & WHI: Guidance on Menopause Management" website (www.howwhenwhi.com) for more information on the rational use of hormone therapy to manage the symptoms of menopause.
The target audience for this activity includes primary care practitioners, OB/GYNs, and other physicians at women’s health centers, as well as NPs and PAs in the above specialties and others who care for menopausal women.
Upon completion of the activity, participants should be able to:
Identify accurate descriptions of the WHI study’s purpose, recruitment methods, and study endpoints vs inaccurate but commonly held misconceptions.
Compare and contrast age-stratified data in the WHI trials of CE alone and CE + MPA.
Select optimal therapy for menopausal symptoms in women with greater estimated benefit than risk, including the appropriate selection of therapies for women with and without a uterus.
There is no fee for this educational activity.
Conflict Of Interest Disclosure Policy
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s).* For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.
*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.
Diane Pace, PhD, APRN, FNP-BC, NCMP, FAANP Associate Professor, The University of Tennessee Health Science Center/Memphis College of Nursing Memphis, TN
Dr. Pace has served or is currently serving as a consultant for Pfizer Inc. and JDS Therapeutics, LLC. She has served or is currently serving on the speaker’s bureaus of Pfizer Inc. and Teva Pharmaceutical Industries Ltd. She has served or is currently serving on the advisory board of Pfizer Inc.; Hologic, Inc.; and JDS Therapeutics, LLC.
Lisa Larkin, MD, FACP, NCMP, IF Lisa Larkin, MD, & Associates Cincinnati, OH
Dr. Larkin is currently serving as a consultant for the Food and Drug Administration under their Pharmaceutical Science and Clinical Pharmacology Advisory Committee; Valeant Pharmaceuticals International, Inc.; and Palatin Technologies, Inc. She also serves on the speaker’s bureau for Valeant Pharmaceuticals International, Inc.
James Simon, MD, CCD, NCMP, IF, FACOG Clinical Professor of Obstetrics and Gynecology, The George Washington University Washington, DC
Dr. Simon’s research has been supported by more than 350 research grants and scholarships from a wide range of sponsors, including the National Institutes of Health, the American Heart Association, The Heinz Foundation, and the pharmaceutical industry. He has authored or coauthored more than 550 peer-reviewed articles, chapters, textbooks, abstracts, and other publications, including several prize-winning papers. Dr. Simon is coauthor of the paperback book, Restore Yourself: A Woman’s Guide to Reviving Her Sexual Desire and Passion for Life. In addition, Dr. Simon has been named among the “Top Washington Physicians,” “America’s Top Obstetricians and Gynecologists,” and “The Best Doctors in America.”
Dr. Simon has served within the last year or is currently serving as a consultant to or on the advisory boards of AbbVie Inc.; AMAG Pharmaceuticals; Amgen Inc.; Apotex Inc.; ASCEND Therapeutics US, LLC; JDS Therapeutics, LLC; Merck & Co., Inc.; Noven Pharmaceuticals, Inc.; Novo Nordisk; Nuelle, Inc.; Perrigo Company plc; Radius Health, Inc.; Regeneron; Sanofi; Sermonix Pharmaceuticals; Shionogi Inc.; Sprout Pharmaceuticals; Symbiotec Pharmalab; and TherapeuticsMD, Inc. He has also served or is currently serving on the speaker’s bureaus of Amgen Inc.; Eisai Inc.; Merck & Co., Inc.; Noven Pharmaceuticals, Inc., Novo Nordisk; and Shionogi Inc. He has received in the last year or is currently receiving grant/research support from AbbVie Inc.; Allergan; Agile Therapeutics; Bayer Pharma AG; New England Research Institutes; Novo Nordisk; Palatin Technologies, Inc.; Symbio, LLC; and TherapeuticsMD, Inc. James A. Simon, MD, PC, has the patent or is the trademark holder for US Patent 4,816,257, March 28, 1989: “Method for Producing an In Vivo Environment Suitable for Human Embryo Transplant.”; US Trademark Reg. No. 3,446,895, registered June 10, 2008: “You Talk…I’ll Listen. We’ll Plan Together”; US Trademark Reg. No. 3,676,269, Registered September 1, 2009; US Trademark Reg. No. 3,760,080, Registered March 16, 2010: “Women’s Health & Research Consultants”; US Trademark Serial No. 86-714,153, “Dr. SIMON SAYS,” registered February 2, 2016. He is a stockholder in Sermonix Pharmaceuticals.
Accredited Provider Disclosure
The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:
Christine Tebben and Stephanie Breslan, MS, of Forefront Collaborative have no financial relationships to disclose relative to the content of this CME activity.
CME Content Review
The content of this activity was independently peer reviewed. The reviewers of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Forefront Collaborative designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity includes discussion of off-label uses of drugs.
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.